Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents()

PURPOSE: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluation of innovative medicines, yet drug development co...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson, Andrew. D.J., Zwaan, C.Michel, Kolb, E.Anders, Karres, Dominik, Guillot, Julie, Kim, Su Young, Marshall, Lynley, Tasian, Sarah K., Smith, Malcolm, Cooper, Todd, Adamson, Peter C., Barry, Elly, Benettaib, Bouchra, Binlich, Florence, Borgman, Anne, Brivio, Erica, Capdeville, Renaud, Delgado, David, Faller, Douglas V., Fogelstrand, Linda, Fraenkel, Paula Goodman, Hasle, Henrik, Heenen, Delphine, Kaspers, Gertjan, Kieran, Mark, Klusmann, Jan-Henning, Lesa, Giovanni, Ligas, Franca, Mappa, Silvia, Mohamed, Hesham, Moore, Andrew, Morris, Joan, Nottage, Kerri, Reinhardt, Dirk, Scobie, Nicole, Simko, Stephen, Winkler, Thomas, Norga, Koen, Reaman, Gregory, Vassal, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789799/
https://www.ncbi.nlm.nih.gov/pubmed/32688206
http://dx.doi.org/10.1016/j.ejca.2020.04.038

Ejemplares similares

Ejemplares similares